カテゴリ： GlobalData, アメリカ, 企業調査

Aduro BioTech Inc (ADRO)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Aduro BioTech Inc (ADRO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C12380
◆発行会社（調査会社）：GlobalData
◆発行日：2018年12月
◆ページ数：80
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Aduro BioTech Inc (Aduro BioTech) is a clinical-stage immunotherapy company that discovers, develops and commercializes therapies for the treatment of cancer. The company develops product candidates using proprietary technology platforms such as live, attenuated, double-deleted listeria, sting pathway activators; and B-select monoclonal antibodies to create immunotherapies for the treatment of cancers, infectious and autoimmune diseases. Its products under development are intended for the treatment of multiple indications, including pancreatic, lung, ovarian, prostate cancers, mesothelioma and glioblastoma. The company collaborates with various pharmaceutical companies to expand its products and technology platforms. Aduro BioTech is headquartered in Berkeley, California, the US.

Aduro BioTech Inc (ADRO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aduro BioTech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Aduro BioTech Acquires GVAX Assets From BioSante Pharma 13
Venture Financing 15
Aduro BioTech Raises USD51.4 Million in Series D Venture Financing 15
Aduro BioTech Raises USD55 Million in Series C Financing 17
Aduro BioTech Raises US$7 Million In Venture Financing 18
Aduro BioTech Raises US$6.5 Million In Venture Financing 19
BioNovion Raises Funds through Venture Financing 20
Partnerships 21
Aduro BioTech Enters into Agreement with Immunotherapeutics and Vaccine Research Initiative 21
HitGen Enters into Agreement with Aduro Biotech 22
Aduro Biotech Expands Agreement with Merck 23
University of California, Berkeley Enters into Agreement with Aduro Biotech 24
Aduro Biotech Enters into Agreement with Novartis for Immuno-Oncology Products 25
BioNovion Enters into Agreement with Genmab to Discover and Develop Multiple Bispecific Antibody Products 26
Aduro BioTech Enters Into Co-Development Agreement With Protein Potential And Sanaria To Develop Malaria Vaccines 27
Licensing Agreements 29
Aduro BioTech Enters into Licensing Agreement with Stanford University 29
Aduro BioTech Amends Licensing Agreement with University of California, Berkeley 30
Merck Enters into Licensing Agreement with BioNovion 31
Aduro BioTech Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center, Rockefeller University, Rutgers and University of Bonn 32
Aduro BioTech Enters into Licensing Agreement with Janssen Biotech 34
Aduro BioTech Enters Into Licensing Agreement With University Of California, Berkeley 35
Aduro BioTech Enters into Licensing Agreement with Janssen Biotech for GVAX technology 36
Aduro BioTech Enters into Licensing Agreement with Johns Hopkins University for GVAX-Related Patent Rights 37
Aduro BioTech Enters into Licensing Agreement with Karagen Pharma 38
Aduro BioTech Enters into Licensing Agreement with UCB 39
Equity Offering 40
Aduro Biotech Plans to Raise Funds through Public Offering of Shares 40
Aduro Biotech Plans to Raise up to USD100 Million in Public Offering of Shares 41
Aduro Biotech to Raise up to USD100 Million in Public Offering of Shares 42
Aduro BioTech Raises USD25 Million in Private Placement Shares 43
Aduro BioTech Raises USD136.8 Million in IPO 44
Acquisition 46
Aduro Biotech Acquires BioNovion 46
Aduro BioTech Inc – Key Competitors 47
Aduro BioTech Inc – Key Employees 48
Aduro BioTech Inc – Locations And Subsidiaries 49
Head Office 49
Other Locations & Subsidiaries 49
Recent Developments 50
Financial Announcements 50
Oct 30, 2018: Aduro Biotech reports third quarter 2018 financial results 50
Aug 01, 2018: Aduro Biotech reports second quarter 2018 financial results 51
May 02, 2018: Aduro Biotech Announces First Quarter 2018 Financial Results 52
Mar 01, 2018: Aduro Biotech Reports Fourth Quarter And Full Year 2017 Financial Results 53
Oct 31, 2017: Aduro Biotech Reports Third Quarter 2017 Financial Results 54
Aug 02, 2017: Aduro Biotech Reports Second Quarter 2017 Financial Results 55
May 02, 2017: Aduro Biotech Reports First Quarter 2017 Financial Results 56
Mar 01, 2017: Aduro Biotech Announces Fourth Quarter and Full Year 2016 Financial Results 57
Corporate Communications 59
Sep 19, 2018: Aduro Biotech Announces the Departure of Natalie R. Sacks 59
Jan 05, 2018: Aduro Biotech Announces Management Changes 60
Jul 27, 2017: Aduro Biotech Announces Andrea van Elsas, Ph.D., to be Named Chief Scientific Officer Effective September 1, 2017 61
Apr 20, 2017: Aduro Biotech Announces Management Promotions 62
Product News 63
12/18/2017: Aduro Biotech Announces the Initiation of a Phase 1/2 Clinical Trial of BION-1301, a Novel Anti-APRIL Antibody, for the Treatment of Multiple Myeloma 63
12/12/2017: Aduro Biotech Provides Update on CRS-207 Programs 64
09/04/2018: Aduro Biotech and Dana-Farber Cancer Institute publish data highlighting immunosuppressive impact of APRIL in multiple myeloma in leukemia 65
03/06/2017: Aduro Biotech Presents Data On BION-1301 at the 2017 American Association for Cancer Research Annual Meeting 66
03/06/2017: Aduro Biotech Presents Data on Vaccine Technology targeting STING at the 2017 American Association for Cancer Research Annual Meeting 67
Clinical Trials 68
Sep 04, 2018: Aduro Biotech presents preclinical data for BION-1301, a first-in-class antibody targeting human APRIL, at the 2018 European Congress of Immunology 68
Apr 17, 2018: Aduro Biotech Presents Preclinical Data of ADU-1604 at the American Association for Cancer Research Annual Meeting 69
Apr 17, 2018: Aduro Biotech Presents Preclinical Data of BION-1301 at the American Association for Cancer Research Annual Meeting 70
Mar 14, 2018: Aduro Biotech to Present Preclinical Data on ADU-1604 at AACR 2018 Annual Meeting 71
Mar 14, 2018: Aduro Biotech to Present Preclinical Data on BION-1301 at AACR 2018 Annual Meeting 72
Nov 10, 2017: Aduro Biotech Announces Promising Preclinical Data that Validate Anti-CTLA-4 Antibody ADU-1604 73
Nov 01, 2017: Aduro Biotech Announces Upcoming Data Presentations at the 59th American Society of Hematology Annual Meeting 74
Sep 27, 2017: Aduro Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Personalized Immunotherapy pLADD Based on Proprietary Neoantigen Technology 75
Aug 09, 2017: Aduro Biotech Bolsters Intellectual Property Position in STING Field with Two New Patents 76
Jun 29, 2017: Aduro Biotech Announces Initiation of Phase 2 Clinical Trial of CRS-207 in Combination with KEYTRUDA (pembrolizumab) for the Treatment of Previously-Treated Gastroesophageal Adenocarcinoma 77
Jun 28, 2017: Aduro Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of CRS-207 in Combination with KEYTRUDA for the Treatment of Patients with Previously Treated Malignant Pleural Mesothelioma 78
May 26, 2017: Aduro Biotech to Host and Webcast an Investor Event in Conjunction with the 2017 ASCO Annual Meeting 79
Appendix 80
Methodology 80
About GlobalData 80
Contact Us 80
Disclaimer 80

List of Tables
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aduro BioTech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aduro BioTech Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Aduro BioTech Acquires GVAX Assets From BioSante Pharma 13
Aduro BioTech Raises USD51.4 Million in Series D Venture Financing 15
Aduro BioTech Raises USD55 Million in Series C Financing 17
Aduro BioTech Raises US$7 Million In Venture Financing 18
Aduro BioTech Raises US$6.5 Million In Venture Financing 19
BioNovion Raises Funds through Venture Financing 20
Aduro BioTech Enters into Agreement with Immunotherapeutics and Vaccine Research Initiative 21
HitGen Enters into Agreement with Aduro Biotech 22
Aduro Biotech Expands Agreement with Merck 23
University of California, Berkeley Enters into Agreement with Aduro Biotech 24
Aduro Biotech Enters into Agreement with Novartis for Immuno-Oncology Products 25
BioNovion Enters into Agreement with Genmab to Discover and Develop Multiple Bispecific Antibody Products 26
Aduro BioTech Enters Into Co-Development Agreement With Protein Potential And Sanaria To Develop Malaria Vaccines 27
Aduro BioTech Enters into Licensing Agreement with Stanford University 29
Aduro BioTech Amends Licensing Agreement with University of California, Berkeley 30
Merck Enters into Licensing Agreement with BioNovion 31
Aduro BioTech Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center, Rockefeller University, Rutgers and University of Bonn 32
Aduro BioTech Enters into Licensing Agreement with Janssen Biotech 34
Aduro BioTech Enters Into Licensing Agreement With University Of California, Berkeley 35
Aduro BioTech Enters into Licensing Agreement with Janssen Biotech for GVAX technology 36
Aduro BioTech Enters into Licensing Agreement with Johns Hopkins University for GVAX-Related Patent Rights 37
Aduro BioTech Enters into Licensing Agreement with Karagen Pharma 38
Aduro BioTech Enters into Licensing Agreement with UCB 39
Aduro Biotech Plans to Raise Funds through Public Offering of Shares 40
Aduro Biotech Plans to Raise up to USD100 Million in Public Offering of Shares 41
Aduro Biotech to Raise up to USD100 Million in Public Offering of Shares 42
Aduro BioTech Raises USD25 Million in Private Placement Shares 43
Aduro BioTech Raises USD136.8 Million in IPO 44
Aduro Biotech Acquires BioNovion 46
Aduro BioTech Inc, Key Competitors 47
Aduro BioTech Inc, Key Employees 48
Aduro BioTech Inc, Other Locations 49
Aduro BioTech Inc, Subsidiaries 49

List of Figures
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Aduro BioTech Inc (ADRO)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Venado Oil & Gas LLC：石油・ガス：M&Aディール及び事業提携情報
    Summary Venado Oil & Gas LLC (Venado) is an oil and gas company that offers oil and gas services. The company explores and develops oil and natural gas properties in the Gulf Coast and Permian regions of Texas. It also provides crude oil and natural gas products. Venado offers services such as execu …
  • Guangzhou Institute of Biomedicine and Health-製薬・医療分野：企業M&A・提携分析
    Summary Guangzhou Institute of Biomedicine and Health (GIBH) is a research institute that conducts research on stem cell and regenerative medicine, chemical biology, infection and immunity, public health and scientific research equipment development. The institute’s life process and disease mechanis …
  • Sutro Biopharma Inc-製薬・医療分野：企業M&A・提携分析
    Summary Sutro Biopharma Inc (Sutro), formerly Fundamental Applied Biology Inc, discovers and develops antibody drug conjugate and multi-specific antibody-based therapeutics. The company develops its pipeline products through Xpress CF platform, a biochemical protein synthesis system, for the treatme …
  • Sumitomo Life Insurance Company：企業のM&A・事業提携・投資動向
    Sumitomo Life Insurance Company - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sumitomo Life Insurance Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • Alta Mesa Resources Inc：企業の戦略的SWOT分析
    Alta Mesa Resources Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • International Paper Co：企業のM&A・事業提携・投資動向
    International Paper Co - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's International Paper Co Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Beazer Homes USA Inc：企業の戦略・SWOT・財務情報
    Beazer Homes USA Inc - Strategy, SWOT and Corporate Finance Report Summary Beazer Homes USA Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • China Mobile Ltd (941)：企業の財務・戦略的SWOT分析
    China Mobile Ltd (941) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Innergex Renewable Energy Inc：発電所・企業SWOT分析
    Innergex Renewable Energy Inc - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • Jollibee Foods Corporation：企業の戦略・SWOT・財務情報
    Jollibee Foods Corporation - Strategy, SWOT and Corporate Finance Report Summary Jollibee Foods Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Thales Deutschland GmbH：企業の戦略・SWOT・財務情報
    Thales Deutschland GmbH - Strategy, SWOT and Corporate Finance Report Summary Thales Deutschland GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Berjaya Sports Toto Berhad：企業の戦略・SWOT・財務情報
    Berjaya Sports Toto Berhad - Strategy, SWOT and Corporate Finance Report Summary Berjaya Sports Toto Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Crown Castle International Corp.：企業の戦略・SWOT・財務情報
    Crown Castle International Corp. - Strategy, SWOT and Corporate Finance Report Summary Crown Castle International Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Banco de Chile：企業の戦略・SWOT・財務情報
    Banco de Chile - Strategy, SWOT and Corporate Finance Report Summary Banco de Chile - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Natcore Technology Inc (NXT)：企業の財務・戦略的SWOT分析
    Summary Natcore Technology Inc (Natcore) is a solar research and development company that provides products for semiconductor and fiber optic applications. The company’s products include solar cell structures and black silicon cells. It uses liquid phase deposition technology for controlling deposit …
  • VAALCO Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    VAALCO Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary VAALCO Energy, Inc. (VAALCO) is an upstream oil and gas company. It acquires, explores, develops and produces crude oil and natural gas from assets. The company conducts the exploration activities …
  • Sanford Burnham Prebys Medical Discovery Institute-製薬・医療分野：企業M&A・提携分析
    Summary Sanford Burnham Prebys Medical Discovery Institute (Sanford Burnham) is a non-profit public benefit institute that offers medical research services. The institute offers research programs in the field of tumor initiation and maintenance, cancer metabolism and signaling networks, tumor microe …
  • Jones Packaging Inc.：企業の戦略的SWOT分析
    Jones Packaging Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Xiangxue Pharmaceutical Co Ltd (300147)：製薬・医療：M&Aディール及び事業提携情報
    Summary Xiangxue Pharmaceutical Co Ltd (XPH) is a pharmaceutical company that manufactures and distributes drugs and medicines. The company’s products include drugs, Chinese medicine pieces, medical instruments, health products and medicinal drinks, among others. It also provides healthcare suppleme …
  • Toyota Motor Corp (7203)：企業の財務・戦略的SWOT分析
    Toyota Motor Corp (7203) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆